Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising VisualAbstract: Combined cagrilintide and semaglutide for weight management well tolerated in early clinical trials 2 Minute Medicine Cagrilintide Peptide for Weight Loss Appetite Control & Metabolic Support Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination